News
News

The latest updates from AFAR.

Grantee in the News: Beeson Scholar Timothy Miller's research on drugs that target Tau reduction

Jan 25
2017

Grantee in the News: Beeson Scholar Timothy Miller's research on drugs that target Tau reduction View MoreBACK

2010 Paul Beeson Career Development Awards in Aging Research Scholar Timothy Miller, MD, PhD, is the senior author of a recently published study in the January 25, 2017 issue of Science Translational Medicine.

In “Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy,” Miller and his co-authors explore how a drug compound has shown to halt Alzheimer’s related damage in mice.

As the Washington University School of Medicine in St. Louis summarizes:

Under ordinary circumstances, the protein tau contributes to the normal, healthy functioning of brain neurons. In some people, though, it collects into toxic tangles that damage brain cells. Such tangles are a hallmark of Alzheimer’s and other neurodegenerative diseases.

But researchers at Washington University School of Medicine in St. Louis have shown that levels of the tau protein can be reduced – and some of the neurological damage caused by tau even reversed ­– by a synthetic molecule that targets the genetic instructions for building tau before the protein is made.

The findings suggest that the molecule – known as an antisense oligonucleotide – potentially could treat neurodegenerative diseases characterized by abnormal tau, including Alzheimer’s.


Timothy Miller, MD, PhD, the David Clayson Professor of Neurology in the Department of Neurology at Washington University School of Medicine in St. Louis

With registration, the published study can be read here.

For more, Washington University School of Medicine in St. Louis shares this release.


For more on Alzheimer’s research, download AFAR’s expert-edited InfoAging Guide on Alzheimer’s Disease here.
 





View MoreBACK TO TOP